Although the anti‐CD19 CAR‐T cell therapy has achieved remarkable results in the treatment of refractory/recurrent (R/R) diffuse large B‐cell lymphoma (DLBCL), the therapeutic effect for the treatment of larger tumors is far from satisfactory. Here, CD19 is linked to diffuse large B-cell lymphoma.